Cargando…

Impact of cannabis use on Schizo-affective disorder

INTRODUCTION: Schizoaffective disorder (SAD) is a nosographic entity characterized by an association of schizophrenic symptoms with thymic episodes. Addictive substance abuse behaviours precede or appear concomitantly with thymic and/or schizophrenic symptoms for the majority of patients. OBJECTIVES...

Descripción completa

Detalles Bibliográficos
Autores principales: Zbidi, M., Bouali, W., Haouari, W., Kacem, M., Khouadja, S., Zarrouk, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660881/
http://dx.doi.org/10.1192/j.eurpsy.2023.1225
_version_ 1785137853385146368
author Zbidi, M.
Bouali, W.
Haouari, W.
Kacem, M.
Khouadja, S.
Zarrouk, L.
author_facet Zbidi, M.
Bouali, W.
Haouari, W.
Kacem, M.
Khouadja, S.
Zarrouk, L.
author_sort Zbidi, M.
collection PubMed
description INTRODUCTION: Schizoaffective disorder (SAD) is a nosographic entity characterized by an association of schizophrenic symptoms with thymic episodes. Addictive substance abuse behaviours precede or appear concomitantly with thymic and/or schizophrenic symptoms for the majority of patients. OBJECTIVES: The objective of our work was to specify the sociodemographic ,clinical and therapeutic characteristics of this population and to compare them to a group of schizophrenic patients who do not use cannabis. METHODS: This is a retrospective descriptive study of patients with Schizoaffective Disorder (SAD) meeting the criteria of the Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association, 5th Version (DSM-5), hospitalized between January 2015 and December 2021 in the psychiatry department of the EPS Tahar Sfar Mahdia. RESULTS: Our sample was composed of two groups: A first group formed by patients with a positive toxicological assessment to tetra-hydro-cannabinol (n=14) and a second group witha negative toxicological assessment (n=36). In SAD subjects using cannabis, the average age at first hospitalization was younger (27.5 years) than in the other groups, hospitalization was earlier (27.27 vs 33.58; p=0.04), the duration in number of days of hospitalization was greater (29.33 vs. 24.67; p=0.02) and they had required during their hospital stay a higher dosage of antipsychotics in equivalent doses of chlorpromazine (723 vs 603; p=0.04). There was a significant difference (p ≤ 0.04) in the psychometric scales (BPRS, SAPS and SANS) in favour of patients who did not use cannabis. CONCLUSIONS: The deleterious psychic effects of chronic cannabis use have long been suspected for a long time. Patients followed for SAD present more frequently than the reference population addictive behaviours towards cannabis which is associated with many negative events affecting clinical symptomatology, evolution, prognosis and therapeutic response. DISCLOSURE OF INTEREST: None Declared
format Online
Article
Text
id pubmed-10660881
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-106608812023-07-19 Impact of cannabis use on Schizo-affective disorder Zbidi, M. Bouali, W. Haouari, W. Kacem, M. Khouadja, S. Zarrouk, L. Eur Psychiatry Abstract INTRODUCTION: Schizoaffective disorder (SAD) is a nosographic entity characterized by an association of schizophrenic symptoms with thymic episodes. Addictive substance abuse behaviours precede or appear concomitantly with thymic and/or schizophrenic symptoms for the majority of patients. OBJECTIVES: The objective of our work was to specify the sociodemographic ,clinical and therapeutic characteristics of this population and to compare them to a group of schizophrenic patients who do not use cannabis. METHODS: This is a retrospective descriptive study of patients with Schizoaffective Disorder (SAD) meeting the criteria of the Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association, 5th Version (DSM-5), hospitalized between January 2015 and December 2021 in the psychiatry department of the EPS Tahar Sfar Mahdia. RESULTS: Our sample was composed of two groups: A first group formed by patients with a positive toxicological assessment to tetra-hydro-cannabinol (n=14) and a second group witha negative toxicological assessment (n=36). In SAD subjects using cannabis, the average age at first hospitalization was younger (27.5 years) than in the other groups, hospitalization was earlier (27.27 vs 33.58; p=0.04), the duration in number of days of hospitalization was greater (29.33 vs. 24.67; p=0.02) and they had required during their hospital stay a higher dosage of antipsychotics in equivalent doses of chlorpromazine (723 vs 603; p=0.04). There was a significant difference (p ≤ 0.04) in the psychometric scales (BPRS, SAPS and SANS) in favour of patients who did not use cannabis. CONCLUSIONS: The deleterious psychic effects of chronic cannabis use have long been suspected for a long time. Patients followed for SAD present more frequently than the reference population addictive behaviours towards cannabis which is associated with many negative events affecting clinical symptomatology, evolution, prognosis and therapeutic response. DISCLOSURE OF INTEREST: None Declared Cambridge University Press 2023-07-19 /pmc/articles/PMC10660881/ http://dx.doi.org/10.1192/j.eurpsy.2023.1225 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Zbidi, M.
Bouali, W.
Haouari, W.
Kacem, M.
Khouadja, S.
Zarrouk, L.
Impact of cannabis use on Schizo-affective disorder
title Impact of cannabis use on Schizo-affective disorder
title_full Impact of cannabis use on Schizo-affective disorder
title_fullStr Impact of cannabis use on Schizo-affective disorder
title_full_unstemmed Impact of cannabis use on Schizo-affective disorder
title_short Impact of cannabis use on Schizo-affective disorder
title_sort impact of cannabis use on schizo-affective disorder
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660881/
http://dx.doi.org/10.1192/j.eurpsy.2023.1225
work_keys_str_mv AT zbidim impactofcannabisuseonschizoaffectivedisorder
AT boualiw impactofcannabisuseonschizoaffectivedisorder
AT haouariw impactofcannabisuseonschizoaffectivedisorder
AT kacemm impactofcannabisuseonschizoaffectivedisorder
AT khouadjas impactofcannabisuseonschizoaffectivedisorder
AT zarroukl impactofcannabisuseonschizoaffectivedisorder